This is highly possible, because survivin [31–38], Mcl-1 [39–47], XIAP [35, 36, 38, 44, 48–55], and cIPA2 [55] play critical roles in pancreatic cancer resistance to treatment, and it is also known that survivin [56–69], Mcl-1 [70, 71] and XIAP [54] are involved in latent CSC drug resistance and function. The gene discussed is MCL1; the disease is pancreatic neoplasm.